Answers are grounded in this paper and cite their sources.
Maribavir at a dose of at least 400 mg twice daily had efficacy similar to that of valganciclovir for clearing CMV viremia among recipients of hematopoietic-cell or solid-organ transplants. A higher incidence of gastrointestinal adverse events - notably dysgeusia - and a lower incidence of neutropenia were found in the maribavir group. (Funded by ViroPharma/Shire Development; EudraCT number, 2010-024247-32.).
No takes yet. Share an insight, caveat, or question.
Maertens et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: